Nuvectis Pharma Stock Performance
| NVCT Stock | USD 9.66 0.31 3.32% |
Nuvectis Pharma holds a performance score of 20 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.15, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Nuvectis Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Nuvectis Pharma is expected to be smaller as well. Use Nuvectis Pharma downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to analyze future returns on Nuvectis Pharma.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nuvectis Pharma are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting fundamental indicators, Nuvectis Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.35 | Five Day Return 10.26 | Year To Date Return 73.47 | Ten Year Return 187.69 | All Time Return 187.69 |
1 | Acquisition by Mosseri Marlio Charles of 17000 shares of Nuvectis Pharma at 4.7 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Bentsur Ron of 4500 shares of Nuvectis Pharma at 4.65 subject to Rule 16b-3 | 12/24/2024 |
3 | Acquisition by Bentsur Ron of 250000 shares of Nuvectis Pharma subject to Rule 16b-3 | 01/02/2025 |
4 | Acquisition by Mosseri Marlio Charles of 5394 shares of Nuvectis Pharma at 14.4 subject to Rule 16b-3 | 01/28/2025 |
5 | Nuvectis Pharma Announces Proposed Public Offering of Common Stock | 02/04/2025 |
6 | Nuvectis Pharma Announces Pricing of 13.5 Million Public Offering of Common Stock | 02/05/2025 |
7 | Nuvectis Pharma Announces Closing of 15. ... | 02/07/2025 |
8 | Insiders Rewarded With US915k Addition To Investment As Nuvectis Pharma Stock Hits US185m | 02/20/2025 |
9 | Market News Alert Nuvectis Pharma Receives 18 Price Target and Buy Rating from Lucid Capital Markets | 02/27/2025 |
10 | Market News Alert Nuvectis Pharmas NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recom... | 03/05/2025 |
11 | Acquisition by Mosseri Marlio Charles of 240000 shares of Nuvectis Pharma at 5.0 subject to Rule 16b-3 | 03/12/2025 |
12 | Acquisition by Mosseri Marlio Charles of 32121 shares of Nuvectis Pharma at 4.64 subject to Rule 16b-3 | 03/19/2025 |
| Begin Period Cash Flow | 19.1 M |
Nuvectis |
Nuvectis Pharma Relative Risk vs. Return Landscape
If you would invest 458.00 in Nuvectis Pharma on December 21, 2024 and sell it today you would earn a total of 477.00 from holding Nuvectis Pharma or generate 104.15% return on investment over 90 days. Nuvectis Pharma is currently generating 1.3495% in daily expected returns and assumes 5.28% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Nuvectis, and 73% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nuvectis Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nuvectis Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nuvectis Pharma, and traders can use it to determine the average amount a Nuvectis Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2556
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | NVCT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.28 actual daily | 47 53% of assets are more volatile |
Expected Return
| 1.35 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.26 actual daily | 20 80% of assets perform better |
Based on monthly moving average Nuvectis Pharma is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nuvectis Pharma by adding it to a well-diversified portfolio.
Nuvectis Pharma Fundamentals Growth
Nuvectis Stock prices reflect investors' perceptions of the future prospects and financial health of Nuvectis Pharma, and Nuvectis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nuvectis Stock performance.
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 202.28 M | ||||
| Shares Outstanding | 23.39 M | ||||
| Price To Book | 22.73 X | ||||
| EBITDA | (22.9 M) | ||||
| Net Income | (19 M) | ||||
| Cash And Equivalents | 13.57 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 8.89 M | ||||
| Current Ratio | 5.20 X | ||||
| Book Value Per Share | 0.50 X | ||||
| Cash Flow From Operations | (12.25 M) | ||||
| Earnings Per Share | (1.11) X | ||||
| Market Capitalization | 209.59 M | ||||
| Total Asset | 18.61 M | ||||
| Retained Earnings | (73.25 M) | ||||
| Working Capital | 9.71 M | ||||
About Nuvectis Pharma Performance
Assessing Nuvectis Pharma's fundamental ratios provides investors with valuable insights into Nuvectis Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nuvectis Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (1.69) | (1.77) | |
| Return On Assets | (1.02) | (1.07) | |
| Return On Equity | (1.96) | (2.05) |
Things to note about Nuvectis Pharma performance evaluation
Checking the ongoing alerts about Nuvectis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nuvectis Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nuvectis Pharma is way too risky over 90 days horizon | |
| Nuvectis Pharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nuvectis Pharma currently holds about 13.57 M in cash with (12.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Nuvectis Pharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 45.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Mosseri Marlio Charles of 32121 shares of Nuvectis Pharma at 4.64 subject to Rule 16b-3 |
- Analyzing Nuvectis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nuvectis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Nuvectis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nuvectis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nuvectis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nuvectis Pharma's stock. These opinions can provide insight into Nuvectis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.